AbbVie is taking steps to offset competitive pressures within the pharmaceutical market, involving Sanofi and Johnson & Johnson.

The entities involved

• AbbVie →

  pharmaceutical company

  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
  • AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
• Sanofi →

  French pharmaceutical company

  • Sanofi and the Association of Science and Technology Centers announced a partnership focused on environmental education.Fri 23:12
  • Industry experts met in San Diego, involving representatives from Sanofi, Cardinal Health, and Marsh.Fri 18:25
• Johnson & Johnson →

  U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer

  • P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Mon 00:50
  • Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Sun 04:04

Related events

• Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.Sep 6
• Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Aug 14
• AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.Sep 4